Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Thomas Müller. (2022) What are the main considerations when prescribing pharmacotherapy for Parkinson’s disease?. Expert Opinion on Pharmacotherapy 23:7, pages 745-750.
Read now
Read now
Thomas Müller. (2022) Perspective: cell death mechanisms and early diagnosis as precondition for disease modification in Parkinson’s disease: are we on the right track?. Expert Review of Molecular Diagnostics 22:4, pages 403-409.
Read now
Read now
Thomas Müller. (2021) Experimental Dopamine Reuptake Inhibitors in Parkinson’s Disease: A Review of the Evidence. Journal of Experimental Pharmacology 13, pages 397-408.
Read now
Read now
Articles from other publishers (28)
Nikolina Kalčec, Nikolina Peranić, Ivan Mamić, Maja Beus, Christopher R. Hall, Trevor A. Smith, Marc Antoine Sani, Petra Turčić, Frances Separovic & Ivana Vinković Vrček. (2023) Selenium Nanoparticles as Potential Drug-Delivery Systems for the Treatment of Parkinson’s Disease. ACS Applied Nano Materials.
Crossref
Crossref
Viviana A. Ruiz-Pozo, Rafael Tamayo-Trujillo, Santiago Cadena-Ullauri, Evelyn Frias-Toral, Patricia Guevara-Ramírez, Elius Paz-Cruz, Sebastián Chapela, Martha Montalván, Tania Morales-López, Daniel Simancas-Racines & Ana Karina Zambrano. (2023) The Molecular Mechanisms of the Relationship between Insulin Resistance and Parkinson’s Disease Pathogenesis. Nutrients 15:16, pages 3585.
Crossref
Crossref
Xiao-Zhong Jing, Xiang-Zhen Yuan, Xingguang Luo, Shu-Yun Zhang & Xiao-Ping Wang. (2023) An Update on Nondopaminergic Treatments for Motor and Non-motor
Symptoms of Parkinson’s Disease. Current Neuropharmacology 21:8, pages 1806-1826.
Crossref
Crossref
Dewei He, Shoupeng Fu, Bojian Ye, Hefei Wang, Yuan He, Zhe Li, Jie Li, Xiyu Gao & Dianfeng Liu. (2023) Activation of HCA2 regulates microglial responses to alleviate neurodegeneration in LPS-induced in vivo and in vitro models. Journal of Neuroinflammation 20:1.
Crossref
Crossref
Gurkaran Singh Baweja, Shankar Gupta, Bhupinder Kumar, Preeti Patel & Vivek Asati. (2023) Recent updates on structural insights of MAO-B inhibitors: a review on target-based approach. Molecular Diversity.
Crossref
Crossref
S. V. Shtaimets, N. G. Zhukova, M. M. Katina, I. A. Zhukova, A. Е. Agasheva & D. A. Novotnyy. (2023) Integrative Analysis of Predictors for Unfavorable Course of Parkinson Disease According to Medical Care Assessment: Cohort Retrospective Study. Kuban Scientific Medical Bulletin 30:1, pages 69-77.
Crossref
Crossref
Valeria Parrales-Macias, Abha Harfouche, Laurent Ferrié, Stéphane Haïk, Patrick P. Michel, Rita Raisman-Vozari, Bruno Figadère, Nicolas Bizat & Alexandre Maciuk. (2022)
Effects of a New Natural Catechol-
O
-methyl Transferase Inhibitor on Two In Vivo Models of Parkinson’s Disease
. ACS Chemical Neuroscience 13:23, pages 3303-3313.
Crossref
Crossref
Obaydah Abd Alkader Alabrahim & Hassan Mohamed El-Said Azzazy. (2022) Polymeric nanoparticles for dopamine and levodopa replacement in Parkinson's disease. Nanoscale Advances 4:24, pages 5233-5244.
Crossref
Crossref
Chandir C. Ramani, R. Jayachandra Babu, Muralikrishnan Dhanasekaran, S.S. Apte & Devaraj Rambhau. (2022) Effect of Surface Charge Density of a w/o/w Emulsion on the Brain Targeting
of Levodopa in Rats for the Treatment of Parkinson’s Disease. Drug Delivery Letters 12:4, pages 302-310.
Crossref
Crossref
Sadakatali S. Gori, Ajit G. Thomas, Arindom Pal, Robyn Wiseman, Dana V. Ferraris, Run-duo Gao, Ying Wu, Jesse Alt, Takashi Tsukamoto, Barbara S. Slusher & Rana Rais. (2022) D-DOPA Is a Potent, Orally Bioavailable, Allosteric Inhibitor of Glutamate Carboxypeptidase II. Pharmaceutics 14:10, pages 2018.
Crossref
Crossref
Elizabeth Bester, Anél Petzer & Jacobus P. Petzer. (2022) Coumarin derivatives as inhibitors of d-amino acid oxidase and monoamine oxidase. Bioorganic Chemistry 123, pages 105791.
Crossref
Crossref
Thomas Müller. (2022)
GOCOVRI
®
(amantadine) extended-release capsules in Parkinson's disease
. Neurodegenerative Disease Management 12:1, pages 15-28.
Crossref
Crossref
Roslyn Lefin, Anél Petzer & Jacobus P. Petzer. (2022) Phenothiazine, anthraquinone and related tricyclic derivatives as inhibitors of monoamine oxidase. Bioorganic & Medicinal Chemistry 54, pages 116558.
Crossref
Crossref
Shwu‐Jiuan Lin, Lily Tai, Yu‐Jie Huang, Yow‐Shieng Uang, Yih Ho, Kuang‐Yang Hsu & Li‐Hsuan Wang. (2021)
Effect of catechin and commercial preparation of green tea essence on the pharmacokinetics of
l
‐dopa in rabbits
. Biomedical Chromatography 35:12.
Crossref
Crossref
Ramón Cacabelos, Iván Carrera, Olaia Martínez, Ramón Alejo, Lucía Fernández‐Novoa, Pablo Cacabelos, Lola Corzo, Susana Rodríguez, Margarita Alcaraz, Laura Nebril, Iván Tellado, Natalia Cacabelos, Rocío Pego, Vinogran Naidoo & Juan C. Carril. (2021) Atremorine in Parkinson's disease: From dopaminergic neuroprotection to pharmacogenomics. Medicinal Research Reviews 41:5, pages 2841-2886.
Crossref
Crossref
Jong‐Min Moon, Hazhir Teymourian, Ernesto De la Paz, Juliane R. Sempionatto, Kuldeep Mahato, Thitaporn Sonsa‐ard, Nickey Huang, Katherine Longardner, Irene Litvan & Joseph Wang. (2021) Non‐Invasive Sweat‐Based Tracking of L‐Dopa Pharmacokinetic Profiles Following an Oral Tablet Administration. Angewandte Chemie International Edition 60:35, pages 19074-19078.
Crossref
Crossref
Jong‐Min Moon, Hazhir Teymourian, Ernesto De la Paz, Juliane R. Sempionatto, Kuldeep Mahato, Thitaporn Sonsa‐ard, Nickey Huang, Katherine Longardner, Irene Litvan & Joseph Wang. (2021) Non‐Invasive Sweat‐Based Tracking of L‐Dopa Pharmacokinetic Profiles Following an Oral Tablet Administration. Angewandte Chemie 133:35, pages 19222-19226.
Crossref
Crossref
Ramón Cacabelos, Iván Carrera, Olaia Martínez, Vinogran Naidoo, Natalia Cacabelos, Gjumrakch Aliev & Juan C. Carril. (2021) Influence of dopamine, noradrenaline, and serotonin transporters on the pharmacogenetics of Atremorine in Parkinson's disease. Drug Development Research 82:5, pages 695-706.
Crossref
Crossref
Caroline D. Binde, Ingunn F. Tvete & Marianne Klemp. (2021) Time until Need for Levodopa among New Users of Dopamine Agonists or MAO-B Inhibitors. Parkinson's Disease 2021, pages 1-7.
Crossref
Crossref
Dong-Fang Zhao, Yu-Fan Fan, Hao-Nan Yu, Fan-bin Hou, Yan-Wei Xiang, Ping Wang, Guang-Bo Ge, Ling Yang & Jian-Guang Xu. (2021) Discovery and characterization of flavonoids in vine tea as catechol-O-methyltransferase inhibitors. Fitoterapia 152, pages 104913.
Crossref
Crossref
Alexandre Vallée, Jean-Noël Vallée & Yves Lecarpentier. (2021) Potential role of cannabidiol in Parkinson’s disease by targeting the WNT/β-catenin pathway, oxidative stress and inflammation. Aging 13:7, pages 10796-10813.
Crossref
Crossref
Thomas Müller, Bernhard Klaus Mueller & Peter Riederer. (2021) Perspective: Treatment for Disease Modification in Chronic Neurodegeneration. Cells 10:4, pages 873.
Crossref
Crossref
Firoz Anwar, Salma Naqvi, Fahad A. Al-Abbasi, Nauroz Neelofar, Vikas Kumar, Ankit Sahoo & Mohammad Amjad Kamal. (2021) Targeting COVID-19 in Parkinson’s Patients: Drugs Repurposed. Current Medicinal Chemistry 28:12, pages 2392-2408.
Crossref
Crossref
Valeria A. Panova, Sergey I. Filimonov, Zhanna V. Chirkova, Mariya V. Kabanova, Anton A. Shetnev, Mikhail K. Korsakov, Anél Petzer, Jacobus P. Petzer & Kyrill Yu Suponitsky. (2021) Investigation of pyrazolo[1,5-a]quinoxalin-4-ones as novel monoamine oxidase inhibitors. Bioorganic Chemistry 108, pages 104563.
Crossref
Crossref
Benjamin Guieu, Jean-Pierre Jourdan, Aurore Dreneau, Nicolas Willand, Christophe Rochais & Patrick Dallemagne. (2021) Desirable drug–drug interactions or when a matter of concern becomes a renewed therapeutic strategy. Drug Discovery Today 26:2, pages 315-328.
Crossref
Crossref
Stephanus J. Cloete, Clarina I. N’Da, Lesetja J. Legoabe, Anél Petzer & Jacobus P. Petzer. (2020) The evaluation of 1-tetralone and 4-chromanone derivatives as inhibitors of monoamine oxidase. Molecular Diversity 25:1, pages 491-507.
Crossref
Crossref
Daniele Urso, K. Ray Chaudhuri, Mubasher A. Qamar & Peter Jenner. (2020) Improving the Delivery of Levodopa in Parkinson’s Disease: A Review of Approved and Emerging Therapies. CNS Drugs 34:11, pages 1149-1163.
Crossref
Crossref
Andrés García-Sánchez, Alejandra Guillermina Miranda-Díaz & Ernesto Germán Cardona-Muñoz. (2020) The Role of Oxidative Stress in Physiopathology and Pharmacological Treatment with Pro- and Antioxidant Properties in Chronic Diseases. Oxidative Medicine and Cellular Longevity 2020, pages 1-16.
Crossref
Crossref